Breaking News

J&J Initiates Phase III ENSEMBLE Trial for COVID-19 Vax

Will enroll up to 60,000 volunteers across three continents to study the safety and efficacy of a single vaccine dose of JNJ-78436735 versus placebo.

By: Contract Pharma

Contract Pharma Staff

Johnson & Johnson has initiated its large-scale, pivotal, multi-country Phase III trial (ENSEMBLE) for its COVID-19 vaccine candidate, JNJ-78436735, being developed by Janssen Pharmaceutical Companies. The initiation of the ENSEMBLE trial follows positive interim results from the Phase I/IIa clinical study, which demonstrated that the safety profile and immunogenicity after a single vaccination were supportive of further development. Based on these results and following discussions with the ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters